Compounds > telmisartan, hydrochlorothiazide drug combination
Page last updated: 2024-11-08

telmisartan, hydrochlorothiazide drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Kinzalkomb: a fixed combination of telmisartan 80 mg and hydrochlorothiazide 125 mg for the treatment of hypertension [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID216293
SCHEMBL ID2516314
MeSH IDM0400843

Synonyms (21)

Synonym
micardis hct
telmisartan-hydrochlorothiazide
485391-74-0
telmisartan, hydrochlorothiazide drug combination
hydrochlorothiazide/telmisartan mixt.
micardisplus
bay98-7103
pritorplus
(1,1'-biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1h- benzimidazol)-1'-yl)methyl)-, mixt. with 6-chloro-3,4-dihydro-2h-1,2,4- benzothiadiazine-7-sulfonamide 1,1-dioxide
bay 98-7103
telma-h
telmisartan and hydrochlorothiazide
telsar-h
telmisartan/hydrochlorothiazide mixt.
kinzalkomb
SCHEMBL2516314
telmisartan/hydrochlorothiazide
Q7697766
DTXSID30964080
6-chloro-1,1-dioxo-3,4-dihydro-2h-1lambda6,2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
telmisartan / hydrochlorothiazide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The incidence and causality of all adverse events (AEs) and laboratory abnormalities occurring during treatment were recorded."( The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies.
Mancia, G; Schumacher, H, 2008)		0.35
" The most frequent suspected adverse reactions were dizziness and headache, which were comparable across groups and studies."( The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies.
Mancia, G; Schumacher, H, 2008)		0.35
" Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects."( Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension.
Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012)		0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" PubMed searches were conducted to identify randomized trials (n = 14) comparing the two agents, alone or combined with hydrochlorothiazide."( Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
Lacourcière, Y, 2013)		0.39
" Hypertensive patients (clinic blood pressure [BP] ≥ 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12."( The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study.
Bilo, G; Parati, G; Redon, J, 2013)		0.39

Dosage Studied

ExcerptRelevanceReference
" Telmisartan is a highly selective blocker of angiotensin II AT1 receptors ("sartans"); it is at least as effective as the classical antihypertensive agents; thanks to its half-life, the longest of all sartans', it provides adequate antihypertensive coverage throughout the whole 24-hour postdose interval and particularly over the last 6 hours of the dosage interval."( [Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension].
Kulbertus, H, 2003)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (43.75)29.6817
2010's18 (56.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.62 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index78.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (29.41%)5.53%
Reviews12 (35.29%)6.00%
Case Studies3 (8.82%)4.05%
Observational1 (2.94%)0.25%
Other8 (23.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label, Six Month Safety Evaluation of the Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Mild-to-Moderate Hypertension [NCT02177487]Phase 3100 participants (Actual)Interventional1999-06-30Completed
An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg [NCT02177500]Phase 3327 participants (Actual)Interventional2000-01-31Completed
Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases) [NCT02262637]4,814 participants (Actual)Observational2003-09-30Completed
An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg. [NCT02177435]Phase 3491 participants (Actual)Interventional1999-02-28Completed
RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients Wit [NCT00890084]2,913 participants (Actual)Observational2009-04-30Completed
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practic [NCT03205137]0 participants (Actual)Observational2022-06-01Withdrawn(stopped due to Sponsor decision)
Evaluation of the Real-life Efficacy and Safety of a Fixed-dose Telmisartan/Hydrochlorothiazide, Including Its Effect on Plasma Potassium and on Glucose and Lipid Metabolism Parameters in Patients With Essential Arterial Hypertension [NCT01392534]1,586 participants (Actual)Observational2010-07-31Completed
A Randomised, Double-Blind, Placebo-Controlled, 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension [NCT00153049]Phase 2583 participants (Actual)Interventional2004-06-30Completed
[NCT01819220]Phase 416 participants (Actual)Interventional2009-04-30Completed
Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II [NCT02242825]8,148 participants (Actual)Observational2006-01-31Completed
A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® Under Real Clinical Conditions With the Goal to Control the Early Morning BP Rise (SURGE II) [NCT02242396]5,248 participants (Actual)Observational2005-08-31Completed
Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II [NCT02242864]1,527 participants (Actual)Observational2006-01-31Completed
Morning Hypertension and Patient Self-monitoring [NCT02243566]2,707 participants (Actual)Observational2006-04-30Completed
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo) [NCT02262611]266 participants (Actual)Observational2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00890084 (8) [back to overview]Absolute Blood Pressure Decrease
NCT00890084 (8) [back to overview]BP Response Rate (Drop of Systolic BP of 10mmHg or More)
NCT00890084 (8) [back to overview]Change in Concomitant Antihypertensive Drugs Given at Study Entry
NCT00890084 (8) [back to overview]Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg
NCT00890084 (8) [back to overview]Percentage of Patients With Blood Pressure < 130/80 mm Hg
NCT00890084 (8) [back to overview]Percentage of Patients With Blood Pressure < 140/90 mm Hg
NCT00890084 (8) [back to overview]Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007
NCT00890084 (8) [back to overview]Treatment Patterns

Absolute Blood Pressure Decrease

systolic blood pressure (NCT00890084)
Timeframe: baseline and 12 weeks

Interventionmm Hg (Mean)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)23.2

[back to top]

BP Response Rate (Drop of Systolic BP of 10mmHg or More)

BP response rate (drop of systolic BP of ≥ 10mmHg) after approximately 12 weeks of treatment with telmisartan (alone or in fixed combination with HCTZ) (NCT00890084)
Timeframe: 12 weeks

InterventionPercentage of patients (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)91.85

[back to top]

Change in Concomitant Antihypertensive Drugs Given at Study Entry

Percentage of patients who had a change in concomitant antihypertensive drugs prescribed at initiation and after 12 weeks. The antihypertensive drugs were changed (which is stopped, titration of dose and started) or not. (NCT00890084)
Timeframe: baseline and 12 weeks

Interventionpercentage of patients (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)13.6

[back to top]

Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg

(NCT00890084)
Timeframe: 12 weeks

Interventionpercentage of patients (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)11.7

[back to top]

Percentage of Patients With Blood Pressure < 130/80 mm Hg

(NCT00890084)
Timeframe: 12 weeks

InterventionPercentage of participants (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)13.2

[back to top]

Percentage of Patients With Blood Pressure < 140/90 mm Hg

% of high risk patients with Blood Pressure < 140/90 mm Hg (NCT00890084)
Timeframe: 12 weeks

InterventionPercentage of participants (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)69.6

[back to top]

Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007

Blood pressure should be reduced to at least below 140/90 mm Hg (systolic/diastolic),and to lower values, if tolerated, in all hypertensive patients. Target blood pressure should be lower than 130/80 mmHg in diabetics and in high or very high risk patients (NCT00890084)
Timeframe: 12 weeks

Interventionpercentage of prescribers (Number)
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)47.7

[back to top]

Treatment Patterns

Treatment patterns observed at the end of the study as Micardis monotherapy, Micardis Plus 12.5 and Micardis Plus 25 (with or without changes in concomitant antihypertensive medications). (NCT00890084)
Timeframe: 12 weeks

InterventionPercentage of patients (Number)
Telmisartan 40mgTelmisartan 80mgTelmisartan 40/12,5mgTelmisartan 80/12,5mgTelmisartan 80/25mg
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)4.749.43.329.712.6

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		4.4322uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		4.9521dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		3.1210benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		12.893210benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		6.3843biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		4.4122C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		3.1810L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		3.1810biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		12.863110benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		2.0110alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
olmesartan medoxomil
Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.		3.1210biphenyls
mepirodipine
mepirodipine: RN & structure given in first source; RN refers to (S,S)-isomer		3.511dihydropyridine
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		3.4111dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
preminent
[no description available]		3.4811
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		012.563010
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		012.563010
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		0310
Diabetes Mellitus, Adult-Onset
[description not available]		03.511
Insulin Sensitivity
[description not available]		03.511
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		03.511
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		03.511
Hypermelanosis
[description not available]		02.1310
Hyperpigmentation
Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.		02.1310
Hyperpotassemia
[description not available]		02.0510
Hyperkalemia
Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)		02.0510
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		02.0510
Dermatitis Medicamentosa
[description not available]		02.0510
Exanthem
[description not available]		02.0510
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		02.0510
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		03.4611
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		03.4611